地塞米松联合重组人白介素11治疗初诊原发免疫性血小板
减少症的近期疗效观察
武令启
【期刊名称】《中国继续医学教育》 【年(卷),期】2016(008)032
【摘要】目的：观察地塞米松联合重组人白介素-11（rhIL-11）治疗初诊原发免疫性血小板减少症（ITP）的近期疗效。方法43例患者分为观察组和对照组，治疗后观察疗效及药物不良反应。结果观察组与对照组总有效率对比，差异无统计学意义，外周血小板达峰值时间，观察组短于对照组。常见不良反应两组比较，差异无统计学意义。结论地塞米松联合rhIL-11治疗初诊ITP，短期疗效显著，安全可靠。%Objective To observe the short-term effects of dexamethasone combined with rhIL-11 in treatment of newly diagnosed ITP.Methods 43 cases of patients were divided into the observation group and the control group. The therapeutic effects and the drug adverse effects were observed respectively.Results The total response rate was not signiifcantly different. In the time of BPC ascending to the peak was significantly different between two groups. The side effects were not significantly different. Conclusion The treatment of newly diagnosed ITP with dexamethasone combined rhIL-11 could results in better short-term therapeutic effects and security. 【总页数】2页(187-188)
【关键词】地塞米松;重组人白介素-11;原发免疫性血小板减少症
【作者】武令启
【作者单位】内蒙古赤峰市第二医院血液科，内蒙古 赤峰 024000 【正文语种】中文 【中图分类】R544.2 【文献来源】
https://www.zhangqiaokeyan.com/academic-journal-cn_china-continuing-medical-education_thesis/0201253889135.html 【相关文献】
1.重组人白介素-11联合大剂量地塞米松治疗成人原发免疫性血小板减少症重症患者短期疗效观察 [J], 王炜; 张征帆
2.大剂量地塞米松联合重组人白介素-11治疗新诊断原发免疫性血小板减少症的观察性研究 [J], 王育丽; 唐宇宏; 司阳; 张彦芳; 朱琦
3.重组人血小板生成素联合地塞米松治疗原发免疫性血小板减少症的疗效探讨 [J], 胡晓萍
4.大剂量地塞米松联合重组人血小板生成素治疗48例成人初治重症原发免疫性血小板减少症的有效性及安全性 [J], 李燕; 黄琴; 王超; 木合塔拜尔; 安利; 王晓敏
5.重组人白介素-11联合激素治疗重症成人原发免疫性血小板减少症的短期临床疗效观察 [J], 季美华; 马海佳; 陈进; 黄泉
以上内容为文献基本信息，获取文献全文请下载
地塞米松联合重组人白介素11治疗初诊原发免疫性血小板减少症的近
